1. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
- Author
-
Nobuyasu Awano, Kazushi Fujimoto, Takehiro Izumo, Mari Tone, Yutaka Muto, Yu Ito, Ayae Saiki, Naoyuki Kuse, Haruko Matsumoto, Keita Sakamoto, Kohei Takada, and Minoru Inomata
- Subjects
Male ,medicine.medical_treatment ,efficacy ,adverse event ,Dexamethasone ,law.invention ,PCR, polymerase chain reaction ,law ,COVID-19, coronavirus disease 2019 ,Janus kinase inhibitor ,Sulfonamides ,Alanine ,Mortality rate ,eGFR, estimated glomerular filtration rate ,ACTT-2, Adaptive COVID-19 Treatment Trial 2 ,Middle Aged ,Intensive care unit ,BRD, baricitinib: remdesivir: and dexamethasone ,Treatment Outcome ,Original Article ,Drug Therapy, Combination ,Female ,severe acute respiratory syndrome coronavirus 2 ,medicine.drug ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Combination therapy ,SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ,coronavirus disease 2019 ,Internal medicine ,medicine ,Humans ,Adverse effect ,IQR, interquartile range ,Aged ,Mechanical ventilation ,SARS-CoV-2 ,business.industry ,COVID-19 ,acute respiratory distress syndrome ,medicine.disease ,Respiration, Artificial ,Adenosine Monophosphate ,COVID-19 Drug Treatment ,Pneumonia ,SpO2, blood oxygen saturation ,Purines ,CTCAE, Common Terminology Criteria for Adverse Events ,Azetidines ,Pyrazoles ,business - Abstract
Background Coronavirus disease 2019 (COVID-19) has spread worldwide and is also an important disease in Japan. Thus, the optimal treatment strategy for severe COVID-19 should be established urgently. The effects of combination treatment with baricitinib—a Janus kinase inhibitor, remdesivir, and dexamethasone (BRD) are unknown. Methods Patients who received combination therapy with BRD at the Japanese Red Cross Medical Center were enrolled in the study. All patients received baricitinib (≤14 d), remdesivir (≤10 d), and dexamethasone (≤10 d). The efficacy and adverse events were evaluated. Results In total, 44 patients with severe COVID-19 were enrolled in this study. The 28-d mortality rate was low at 2.3% (1/44 patients). The need for invasive mechanical ventilation was avoided in most patients (90%, 17/19 patients). Patients who received BRD therapy had a median hospitalization duration of 11 d, time to recovery of 9 d, duration of intensive care unit stay of 6 d, duration of invasive mechanical ventilation of 5 d, and duration of supplemental oxygen therapy of 5 d. Adverse events occurred in 15 patients (34%). Liver dysfunction, thrombosis, iliopsoas hematoma, renal dysfunction, ventilator-associated pneumonia, infective endocarditis, and herpes zoster occurred in 11%, 11%, 2%, 2%, 2%, 2%, and 2% of patients, respectively. Conclusions Combination therapy with BRD was effective in treating severe COVID-19, and the incidence rate of adverse events was low. The results of the present study are encouraging; however, further randomized clinical studies are needed.
- Published
- 2021